Krystal Biotech (KRYS) Common Equity (2016 - 2026)

Krystal Biotech has reported Common Equity for 11 years, with the latest figure at $1.4 billion in Q2 2026.

• Common Equity for Q2 2026 came in at $1.4 billion, up 30.6% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.4 billion (up 30.6% YoY), and the FY2025 annual result was $1.2 billion, up 28.87% from the prior year.
• Common Equity advanced to $1.4 billion in Q2 2026, from $1.3 billion in the prior quarter.
• Over five years, Common Equity peaked at $1.4 billion in Q2 2026 and troughed at $489.6 million in Q1 2023.
• A 5-year average of $852.1 million and a median of $819.1 million in 2024 frame the typical range for Common Equity.
• The widest annual swing landed in 2022, when Common Equity retreated 12.02%; it then soared 63.26% in 2024.
• A 5-year view of Common Equity shows it stood at $522.2 million in 2022, then soared by 49.1% to $778.6 million in 2023, then rose by 21.54% to $946.4 million in 2024, then climbed by 28.87% to $1.2 billion in 2025, then climbed by 11.44% to $1.4 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $1.4 billion in Q2 2026, $1.3 billion in Q1 2026, and $1.2 billion in Q4 2025.